Seattle’s Athira Pharma files for IPO to fund quest for Alzheimer’s and Parkinson’s breakthroughs
Athira Pharma, which develops therapies for brain diseases such as Alzheimer’s and Parkinson’s, filed for an IPO last week. Athira’s regenerative technology works to rebuild connections between neurons in patients who have nerve damage in their brain. The company has reported positive initial results from a December 2019 clinical trial, and has raised over $100 million in funding to date.